行情回顾：01.04-01.17 期间，医药生物板块涨幅为1.07%，在所有板块中位列第十五，跑输沪深300 指数3.5 个百分点。从子板块看，01.04-01.17 期间，医疗器械、中药、医药商业和医疗服务涨跌幅分别为5.01%、3.43%、2.22%和1.93%，跑赢整体板块；生物制品和化学制药涨跌幅分别为-0.98%和-2.91%，跑输整体板块。

本报告期（2021.1.4-2021.1.15）医药生物行业指数涨幅为0.40%，在申万28 个一级行业中位居第16，跑输沪深300 指数（4.74%）。从子行业来看，医药生物三级行业医疗器械、中药、医疗服务行业涨幅居前，涨幅分别为5.09%、2.31%、1.82%。

市场回顾：2021 年1 月上半月（1.4-1.15）申万医药指数上涨0.49%，跑赢创业板指数，大幅跑输沪深300 指数，位列全行业第12；子行业方面，医疗器械涨幅最大，化学制剂涨幅最末，排名依次为医疗器械(4.84pp)、医疗服务(3.16pp)、医药商业(2.32pp)、中药(0.08pp)、生物制品(-1.68p)、化学原料药(-1.69pp)、化学制剂(-2.57pp)。估值方面，2021 年1 月15 日申万医药平均PE 为45.30 倍，相对沪深300 溢价率117.08%，处于历史中位。

国外现有防疫力度无法阻止疫情在冬季蔓延北半球进入冬季以来，全球疫情再次恶化。全球（不含中国）单日新增数据在2020 年10 月底至11 月初之间迅速攀升，按照大部分国家在冬季的防疫表现，其现有防疫措施力度远不足以遏制疫情在低温天气下的传播，除非未来能实行更为严格的物理隔离措施。

2021 年1 月15 日，国家组织药品集中采购和使用联合采购办公室发布《全国药品集中采购文件（GY-YD2021-1）》，第四批国家层面药品集采将于2月3 日开标。

创新及CXO、药 店、疫苗等有望延续高增长。我们对重点覆盖的 56 家医药上市公司2020 全年业绩进行了预测，其中预计全年业绩增速超过50%的有14家；净利润增速30%-50%的有10 家；净利润增速15%-30%的有10 家；净利润增速0%-15%的有11 家；净利润同比下滑的公司有10 家。分行业来看，器械、CXO、疫苗、药店等板块延续高景气度实现较快增长。

上周恒生医疗保健业指数上涨3.56%，同期香港恒生指数上涨3.72%，医药板块略低于大市，Biotech 子板块表现靓丽。上周JP 摩根医疗大会线上召开，国内多家Biotech 企业包括百济神州(6160.HK)、亚盛医药（6855.HK）等在会上发布了产品研发进展，获得高关注度。

2021年1月15日 ，国家组织药品集中采购和使用联合采购办公室发布《全国药品集中采购文件（GY-YD2021-1）》。本次集采共涉及45 个品种、80 个品规。预计于2 月3 日正式开标。

Digital polymerase chain reaction (dPCR) is a biotechnological advancement of the conventional PCR procedure, as traditional PCR—with its limited precision and accuracy—often fails to amplify small samples of nucleic acids that include RNA, cDNA, or DNA to a detectable level. For the purpose of analysis, the report segments the global digital polymerase chain reaction market into technology, type, application, end user, and region. The scope of the report includes revenue generated by the dPCR system that is used by various, end users including clinical diagnostic laboratories, pharmaceuticals & biotechnology industries, universities, and other organizations. The revenue of different products used during PCR procedure such as reagents & consumables, instruments, software, and services has been included in the report. Furthermore, the applications covered in the study include research, clinical diagnostics, and forensic & others. In addition, it highlights the details about various technologies such as droplet digital PCR (ddPCR) and BEAMing digital PCR. Moreover, it outlines the details about the revenue generated from the sale of dPCR products & services across North America, Europe, Asia-Pacific, and LAMEA.

The scope of the report is limited to revenue generated from sales of shunts used in treatment of hydrocephalus. These products include ventriculo-peritoneal (VP) shunts, ventriculo-atrial (VA) shunts, ventriculo-pleural (VPL) shunts, and lumbo-peritoneal (LP) shunts. However, the report does not include revenue generated from consultation fees, doctor fees, or post-sales services of shunts. Drivers, restraints, and opportunities in the market are provided to understand the market dynamics.b